-+ 0.00%
-+ 0.00%
-+ 0.00%

Oryzon Reports 95% Response Rate for Iadademstat Combination in Phase Ib AML Trial

PUBT·11/04/2026 14:34:05
Listen to the news
Oryzon Reports 95% Response Rate for Iadademstat Combination in Phase Ib AML Trial
  • Oryzon Genomics will present updated iadademstat trial results at the American Society of Hematology meeting in New Orleans, December 12-15, 2026.
  • Phase Ib ALICE-2 results showed encouraging remissions with manageable safety in newly diagnosed acute myeloid leukemia, supporting planned Phase III development.
  • The Phase Ib FRIDA combination showed encouraging remissions with manageable safety in heavily pretreated patients with FLT3-mutated, relapsed or refractory leukemia.
  • Early Phase II results in advanced myeloproliferative neoplasms showed preliminary activity, with no dose-limiting toxicities observed during ongoing dose escalation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oryzon Genomics SA published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.